CRISPR Therapeutics AG (BSP:C2RS34) Cyclically Adjusted FCF per Share: R$-1.37 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:C2RS34 CRISPR Therapeutics AG BSP:C2RS34
16 GF Score
Price R$33.57
GF Value R$2.68
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Cyclically Adjusted FCF per Share?

CRISPR Therapeutics AG BSP:C2RS34 16 Cyclically Adjusted FCF per Share is R$-1.37 as of Jun. 2026. GuruFocus rates BSP:C2RS34 with a GF Score™ of 16/100 and a GF Value™ of R$2.68 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

CRISPR Therapeutics AG's adjusted free cash flow per share for the three months ended in Jun. 2026 was R$-4.599. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$-1.37 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-10), CRISPR Therapeutics AG's current stock price is R$33.57. CRISPR Therapeutics AG's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was R$-1.37. CRISPR Therapeutics AG's Cyclically Adjusted Price-to-FCF of today is .


CRISPR Therapeutics AG  (BSP:C2RS34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


CRISPR Therapeutics AG Cyclically Adjusted FCF per Share Related Terms


CRISPR Therapeutics AG Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Cyclically Adjusted FCF per Share Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CRISPR Therapeutics AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.37

BSP:C2RS34 vs MANE, EWTX, CAI: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, CRISPR Therapeutics AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Cyclically Adjusted Price-to-FCF falls into.


BSP:C2RS34
16GF Score
CRISPR Therapeutics AG BSP:C2RS34
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CRISPR Therapeutics AG's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-4.599/108.5600*108.5600
=-4.599

Current CPI (Jun. 2026) = 108.5600.

CRISPR Therapeutics AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -1.128 99.604 -1.229
201612 -1.452 99.380 -1.586
201703 -2.102 100.040 -2.281
201706 -1.429 100.285 -1.547
201709 -1.474 100.254 -1.596
201712 -1.224 100.213 -1.326
201803 -1.661 100.836 -1.788
201806 -2.072 101.435 -2.218
201809 -1.791 101.246 -1.920
201812 -2.205 100.906 -2.372
201903 -3.306 101.571 -3.533
201906 -2.795 102.044 -2.973
201909 9.366 101.396 10.028
201912 0.165 101.063 0.177
202003 -4.430 101.048 -4.759
202006 -2.778 100.743 -2.994
202009 -6.253 100.585 -6.749
202012 -6.308 100.241 -6.832
202103 -8.090 100.800 -8.713
202106 48.663 101.352 52.124
202109 -8.191 101.533 -8.758
202112 -6.738 101.776 -7.187
202203 -9.720 103.205 -10.224
202206 -9.871 104.783 -10.227
202209 -7.476 104.835 -7.742
202212 -8.002 104.666 -8.300
202303 0.380 106.245 0.388
202306 -8.487 106.576 -8.645
202309 -2.673 106.570 -2.723
202312 -5.952 106.461 -6.069
202403 6.638 107.355 6.713
202406 -6.107 107.991 -6.139
202409 -6.960 107.468 -7.031
202412 -3.589 107.128 -3.637
202503 -3.628 107.722 -3.656
202506 -8.853 108.075 -8.893
202509 -4.976 107.710 -5.015
202512 -5.326 107.200 -5.394
202603 -5.956 108.060 -5.984
202606 -4.599 108.560 -4.599

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of R$-1.37 mean?
CRISPR Therapeutics AG (BSP:C2RS34) has a Cyclically Adjusted FCF per Share of R$-1.37 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Cyclically Adjusted FCF per Share too high?
CRISPR Therapeutics AG's current Cyclically Adjusted FCF per Share is R$-1.37. Overall, CRISPR Therapeutics AG has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Cyclically Adjusted FCF per Share compare to MANE and EWTX?
CRISPR Therapeutics AG's Cyclically Adjusted FCF per Share of R$-1.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Cyclically Adjusted FCF per Share is R$-1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (BSP:C2RS34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$2.68, compared to a current price of R$33.57 — trading 1152.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is R$-1.37. CRISPR Therapeutics AG's overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For CRISPR Therapeutics AG (BSP:C2RS34), the current Cyclically Adjusted FCF per Share is R$-1.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (BSP:C2RS34) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of R$33.57 is trading 1152.6% above its estimated GF Value™ of R$2.68. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for BSP:C2RS34:

  • Cyclically Adjusted FCF per Share: R$-1.37
  • GF Value™: R$2.68 vs. price of R$33.57 (1152.6% above fair value)
  • GF Score™: 16/100 with 3 warning signs

No single metric tells the full story. See the BSP:C2RS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
16GF Score

Get the complete analysis for BSP:C2RS34

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$33.57
Price
R$2.68
GF Value